ArticleCureus2026
Thyroid-Stimulating Hormone Immunoassay Interference Presenting as Treatment-Refractory Hypothyroidism: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Measurement of thyroid-stimulating hormone (TSH) is fundamental for the diagnosis and therapeutic monitoring of hypothyroidism. Elevated TSH levels, with or without abnormalities in free thyroxine, typically indicate thyroid dysfunction and inform levothyroxine dose adjustments. Although suboptimal TSH control is most commonly attributed to poor medication adherence or improper administration, immunoassay-based TSH measurements are susceptible to analytical interference from sources such as biotin supplementation, heterophile antibodies, and macro-TSH complexes. These interferences may yield misleading biochemical results, potentially resulting in misdiagnosis, unnecessary investigations, and inappropriate escalation of therapy. We describe a case of a 53-year-old woman with persistently elevated TSH despite progressive levothyroxine dose escalation to 2.5 μg/kg/day, initially considered treatment-refractory hypothyroidism. Further evaluation ultimately identified TSH assay interference. This case highlights the importance of considering analytical artifacts when clinical and biochemical findings are discordant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.